• Rapid Dose Therapeutics agreed on October 30, 2026, to convert up to $500,000 in outstanding accounts payable into common shares.
• Creditors will receive up to 5,000,000 common shares at $0.10 each, reducing existing liabilities.
• The debt settlement remains subject to Canadian Securities Exchange acceptance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapid Dose Therapeutics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610301619NEWSFILECNPR____20261030_321905_1) on October 30, 2026, and is solely responsible for the information contained therein.